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Chloro-s-triazines, introduced in the late
1950s, include atrazine (ATR), simazine,
propazine, terbutylazine, and cyanazine
(Worthing and Walker 1987). These com-
pounds have been heavily used as herbicides
(Gysin and Knuesli 1960) and are commonly
used to control growth of broadleaf weeds and
grasses on crops such as corn, sugar cane, and
sorghum [U.S. Environmental Protection
Agency (EPA) 1997]. Chlorotriazines are fre-
quently detectable in both ground and surface
waters nationwide (Balu et al. 1998; U.S. EPA
2001; U.S. Geological Survey 1999; Wade
et al. 1997), sometimes at levels exceeding the
U.S. EPA maximum contaminant level of
3 ppb (U.S. EPA 2003b) for ATR. 
ATR is catabolized by plants, microbes,
and animals to yield four major metabolites
(Figure 1): hydroxyatrazine (HA; 6-hydroxy-
N-ethyl-N´-isopropyl-[1,3,5]triazine-2,4-
diamine), diaminochlorotriazine (DACT;
6-chloro[1,3,5]triazine-2,4-diamine),
deisopropylatrazine (DIA; 6-chloro-N-ethyl-
[1,3,5]triazine-2,4-diamine), and deethyl-
atrazine (DEA; 6-chloro-N-isopropyl-
[1,3,5]triazine-2,4-diamine). Other chloro-
triazines used in addition to or instead of
ATR in the field, such as propazine and
simazine, are similarly metabolized. 
Because of their widespread environmental
contamination in the United States, concern
has been raised over the potential health effects
these compounds may have on humans and
wildlife species. Even after successful use
restrictions, recent studies have detected ATR
and its mercapturic acid derivatives in the
urine of both farmers and nonfarmers, suggest-
ing the general population is exposed to and
excreting the herbicide (Curwin et al. 2005;
Norrgran et al. 2006). Statewide groundwater
monitoring and self-imposed minimum
reporting levels for ATR and its chlorinated
metabolites have been implemented in states
growing a large percentage of their farm
acreage in these crops [Illinois Department of
Agriculture (IDA) 2006]. Reports indicate that
about 18% of all samples of Illinois groundwa-
ter collected in 2002–2004 contained more
than the minimum reporting levels (1.5 ppb)
of one or more of the chlorinated ATR
metabolites, yet few samples (< 2%) contained
detectable ATR (IDA 2006). 
ATR metabolites are relatively persistent in
groundwater and soil/sediment, with mean
aerobic and anaerobic soil half-lives ranging
from 20–146 and 58–547 days, respectively,
and aerobic aquatic half-life about 2-fold higher
(Giddings et al. 2005). However, the half-life
is much shorter in the rat. Approximately 85%
of ATR-derived radioactivity, administered as
14C-labeled ATR, is excreted in the urine and
feces of the rat in the ﬁrst 72 hr after oral dos-
ing (Bakke et al. 1972), with the majority of
that excretion (85–95%) occurring in the ﬁrst
24 hr. 
Despite its relatively short half-life in the
adult rat (< 1 day), many laboratories have
shown that ATR administration adversely
affects the endocrine system and reproductive
tissue development in the rat (reviewed by
Dooley et al. 2006). Long-term dietary expo-
sure to 400 ppm ATR (~ 22.5 mg/kg) caused
an early onset of mammary tumors in Sprague-
Dawley rats, and the appearance of tumors was
mediated by ATR-induced premature repro-
ductive aging (Eldridge et al. 1994b, 1998,
1999a, 1999b). Yet, these findings have
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BACKGROUND: Atrazine (ATR), a widely used chlorotriazine herbicide, inhibits a number of
endocrine-dependent processes, including gonadotrophin surges and mammary gland development
in rats. Chlorotriazine herbicides are rapidly metabolized in plants and animals to form a group of
metabolites that are detected both in the environment and in exposed animals. The extent to which
these metabolites are responsible directly for the observed health effects is not understood. 
OBJECTIVES: Our goal was to determine if a mixture of ATR metabolites, in proportions found in
the environment, might produce developmental effects in Long-Evans rats following exposure late
in pregnancy. 
METHODS: We administered an ATR metabolite mixture (AMM) containing ATR, hydroxyatrazine,
diaminochlorotriazine, deethylatrazine, and deisopropylatrazine orally to pregnant Long-Evans rats
at 0.09, 0.87, or 8.73 mg/kg body weight (bw)/day, on gestation days 15–19, using 0 and 100 mg
ATR/kg bw/day as negative and positive controls, respectively. 
RESULTS: We observed no signiﬁcant effect of acute AMM exposure on body weight gain in dams
during the dosing period, weight loss in pups on postnatal day (PND)4, or pubertal timing, as is
seen with ATR alone. However, as with ATR, we detected delayed mammary gland development,
evaluated by whole mount analysis, as early as PND4 in all treatment groups. 
CONCLUSIONS: Our data suggest that acute exposure to AMM at levels as low as 0.09 mg/kg bw
during late pregnancy causes persistent alterations in mammary gland development of female off-
spring, and that these effects do not appear to be related to bw or associated with pubertal timing.
KEY WORDS: atrazine, body weight, development, mammary gland, metabolites, mixture, prenatal
exposure, puberty. Environ Health Perspect 115:541–547 (2007). doi:10.1289/ehp.9612 available
via http://dx.doi.org/ [Online 18 December 2006]limited relevancy to human health because the
condition of premature reproductive aging in
the rat does not occur by the same process in
women. Furthermore, the onset of rat mam-
mary tumors was not increased after ATR-
exposure in ovariectomized females (Eldridge
et al. 1998). 
Other pertinent developmental reproduc-
tive tissue effects have been demonstrated.
ATR delays signs of puberty in both females
and males when administered via oral gavage
according to the “pubertal protocol,” described
in the Endocrine Disruptor Screening Program
(EDSP) Tier II screens (Laws et al. 2000;
Stoker et al. 2000); it also causes full litter
resorption in Fisher 344 rats (Narotsky et al.
2001). Other studies examined the effects of
individual ATR metabolites on puberty in
female and male Wistar rats (Laws et al. 2003;
Stoker et al. 2002). These investigators found
that DACT delayed puberty in female rats,
and DIA, DEA, and DACT delayed puberty
in males. They concluded that the molar
equivalents of ATR’s chlorinated metabolites
were as potent as ATR itself, suggesting that
the metabolites themselves may mediate the
effects of ATR seen in previous studies. Several
studies have shown that ATR and its individ-
ual metabolites cause an alteration of normal
patterns of ovarian and estrous cyclicity when
administered to adult female Long-Evans,
Fisher 344, or Sprague-Dawley rats (Cooper
et al. 1996, 2000; Eldridge et al. 1994a,
1999b; Wetzel et al. 1994). Although ATR
appeared to have antiestrogenic effects, it was
also shown to have insignificant estrogen
receptor binding and activation capability
(Tennant et al. 1994). 
A key ATR study (Cooper et al. 2000)
showed that ATR (50–300 mg/kg by gavage)
speciﬁcally inhibits the estrogen-induced surges
of luteinizing hormone (LH) and prolactin
(PRL) in ovariectomized Long-Evans and
Sprague-Dawley rats, and therefore disrupts
hypothalamic–pituitary–ovarian feedback
loops. This study suggested the brain was the
site of action for ATR, triggering further studies
in the area of neuroendocrine action(s) of ATR
(U.S. EPA 2003a). The current chronic refer-
ence dose (RfD; 0.018 mg/kg/day) is based on
a 6-month rat feeding study using LH surge
and estrous cycle alterations as the biomarkers
of ATR’s potential to disrupt the hypothala-
mic–pituitary axis (U.S. EPA 2002). The acute
RfD is > 5 times higher (0.1 mg/kg/day) and is
based on the no observed adverse effect level
(NOAEL) of 12.5 mg/kg/day (using a
100-fold safety factor) for diminished suck-
ling–induced PRL surge (dam effect) and
increased prostatitis in male Wistar rat off-
spring (Stoker et al. 1999). The only metabo-
lite for which an acute RfD has been
established is DACT (based on a developmen-
tal toxicity NOAEL of 2.5 mg/kg/day), the
ﬁnal breakdown product of the chlorotriazines
(U.S. EPA 2002), yet there is no set maximum
contaminant level for any of the chlorotriazine
metabolites (U.S. EPA 2001). 
After the acute ATR and DACT RfDs
were established, Rayner et al. (2004) showed
that a brief exposure to 100 mg ATR/kg bw
in utero or via lactational ATR residuals delays
female mammary gland development and vagi-
nal opening (VO) in Long-Evans rats. In addi-
tion, the mammary effects in female offspring
(delayed branching morphogenesis, fewer
ducts) following acute prenatal exposure con-
tribute to signiﬁcantly decreased weight gain in
an F2 generation without further exposure
(Rayner et al. 2005). A 3-day exposure to ATR
during late gestation was sufficient to cause
these persistent effects. We do not currently
know the mechanism by which ATR affects
mammary gland development. Because ATR is
rapidly metabolized in the body, it is possible
that ATR metabolites mediate these effects.
However, the effects of acute gestational expo-
sure to ATR metabolites as a mixture (as they
may occur in ground/surface water), or the
individual metabolites, have not been exam-
ined at low doses. 
The objective of these studies was to
address the extent to which acute prenatal
exposure to an ATR metabolite mixture
(AMM; at relatively low doses) affects repro-
ductive development of rat offspring. We
specifically focus on the mammary gland as
an outcome because it appears to be the
reproductive tissue most sensitive to the
effects of the mixture, at doses below the cur-
rent acute developmental NOAEL for ATR
of 6.25 mg/kg/day and the lowest observed
adverse effect level of 12.5 mg/kg/day (U.S.
EPA 2003a).
Materials and Methods
Animals. We obtained timed-pregnant Long-
Evans rats (9–15 weeks of age; sperm positive
= day 0) from Charles River Breeding
Laboratories (Raleigh, NC). We housed
females in clear plastic cages in a facility
accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care.
Cages contained heat-treated pine shavings
(Beta Chips, North Eastern Products Inc.,
Warrensburg, NY), and animals were given
food (Purina 5008 Rodent Chow; Ralston
Purina Co., St. Louis, MO) and water ad libi-
tum. They were maintained in a room with a
14:10-hr light cycle (lights out at 2100 hours)
and treated humanely and with regard for alle-
viation of suffering, as required by the
National Health and Environmental Effects
Research Laboratory Institutional Animal
Care and Use Committee.
Dosing solutions. We prepared ATR and
all metabolites (94.5–98.2% purity; Syngenta
Crop Protection, Inc., Greensboro, NC) as a
suspension in 1.0% methylcellulose (Sigma
Chemical, St. Louis, MO) in distilled water.
We formulated the AMM to contain ATR and
its metabolites (Figure 1) in proportions and at
levels reported in a survey of groundwater and
surface water potentially contaminated by
ATR (Balu et al. 1998; U.S. EPA 2001; U.S.
Geological Survey 1999; Wade et al. 1997).
Our AMM consisted of ATR (25%), HA
(20%), DACT (35%), DEA (15%), and DIA
(5%). We decided on the base AMM concen-
tration (arbitrarily set at 250 ppm) using com-
bined maximum ATR and metabolite
concentrations detected in these sources. We
based the mass given to the rats on an esti-
mated 2 L/day water consumption of a woman
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Deisopropylatrazine (DIA) Diaminochlorotriazine (DACT) Deethylatrazine (DEA)
Figure 1. Structures of the environmental metabolites of two chlorotriazine herbicides, ATR, and simazine.
ATR can be metabolized to HA, DIA, or DEA. The DEA and DIA forms are both quickly converted to DACT. wieghing 70 kg during her third trimester of
pregnancy. We used adjusted molar equiva-
lents to compare relative potency of the
metabolites to ATR in future studies. Dose
groups included 0 (1% methylcellulose vehi-
cle), 0.09 (100 times the base AMM,
2.5 ppm), 0.87 (25 ppm), and 8.73 (250 ppm)
mg AMM/kg bw/day, and 100 mg ATR/kg
bw/day, which were delivered in a volume of
5.0 mL vehicle/kg bw. The 250-ppm dose cal-
culations are shown in Table 1, and subse-
quent doses were made by serial dilution.
Experimental design. We conducted the
study, as summarized in Figure 2, in two repli-
cates (blocks) with ﬁve treatment groups per
block (positive and negative controls present in
each block). We oral gavaged pregnant Long-
Evans rats (n ≥ 6/treatment/block) with 0,
0.09, 0.87 or 8.73 mg AMM/kg bw/day or
100 mg ATR/kg bw/day on gestation day
(GD)15–GD19. We administered half doses
twice daily (0700 and 1400 hours), adjusted
for morning bw. We chose the 100-mg/kg
dose to compare directly with results from our
previous studies (Rayner et al. 2004, 2005).
On prenatal day (PND)4, we weighed pups
and equalized litters to six female pups and
four male pups.
Necropsy. We conducted a necropsy of
female pups (2 pups/dam; n ≥ 5 dams, at each
time) on PNDs 4, 25, 33, 40, and 60
(Figure 2). We used male pups in a separate
study. Animals on PNDs 4, 33, 40, and 60
were decapitated, and PND25 animals were
asphyxiated with CO2. We removed mam-
mary glands (fourth and fifth) for whole-
mount examination at all time points. We
weighed, decapitated, and collected trunk
blood from remaining females [n = 7–16 pups/
treatment group (n ≥ 5 dams each)/block] on
PND60. We removed and weighed the ante-
rior pituitary, uterus, and ovaries devoid of fat.
The contralateral mammary glands, ovaries,
and uterus were ﬁxed in 10% buffered forma-
lin for histologic examination. We separated
serum from the blood of female offspring and
froze it at –80°C for measuring levels of thy-
roid-stimulating hormone (TSH), LH, and
PRL by radioimmunoassays. We froze the
anterior pituitary gland at –80°C for PRL and
LH assays. 
Mammary whole mounts. In all experi-
ments, we removed, fixed, and stained in
carmine the fourth and/or fifth inguinal
mammary glands as a whole mount, as previ-
ously described (Fenton et al. 2002). We
examined whole mounts at 16× magniﬁcation
on a Leica WILD M420 Macroscope (Leica
Microsystems, Heerbrugg, Switzerland); two
individuals without knowledge of treatment
group scored them subjectively (scale of 1–4; 1
= poor development/structure, and 4 = normal
development/structure). The specific criteria
for scoring varied depending on the age of the
group being evaluated, but they included the
number of primary, secondary, and lateral
branchings; the longitudinal growth toward
the lymph node; budding patterns (or lack
thereof); and the presence of terminal end buds
or ducts. This scoring system has been previ-
ously shown to be associated with the actual
numbers of branch points or terminal struc-
tures in rat mammary tissue (Fenton et al.
2002). We separated tissues (lacking identify-
ing information) by developmental score as
they were evaluated, compared each tissue
within a score for consistency, recorded data,
and then translated unique identifying infor-
mation. We captured images of glands repre-
sentative of the mean score of the group using
a Photometrics CoolSNAP camera running
RSImage 1.9.2 (Roper Scientiﬁc, Inc., Tucson,
AZ) for Windows (Microsoft Corporation,
Redmond, WA). 
Histology. We removed the fourth inguinal
mammary gland on PND60 for histologic
assessment of terminal structures. We com-
pressed the glands in cassettes in two changes
of 10% buffered formalin for 48 hr each, at
room temperature. We then transferred ﬁxed
glands to 70% ethanol, processed them in
paraffin, cut them into 5-µm sections, and
stained them in hematoxylin and eosin. On
PND60, we also ﬁxed the ovaries and uterus in
formalin for at least 48 hr. These tissues were
rinsed and stored in 70% alcohol until embed-
ded in parafﬁn, sectioned (5 µm), and stained
with hematoxylin and eosin. We viewed all
sectioned tissues by light microscopy on a Leitz
Laborlux microscope (100× magniﬁcation; E.
Leitz, Leica Microsystems) for any detectable
abnormalities. 
Vaginal opening and estrous cyclicity.
Beginning on PND28, we observed all female
offspring in this study surviving past weaning
for VO, assessed by the presence of a fully
opened vagina, and recorded weight at VO.
Vaginal smears (as described by Cooper et al.
1999) were conducted beginning on PND42,
for the animals surviving past PND40, and
continued until PND60. We classified the
vaginal smears as described by Everett (1989)
and defined extended estrus as exhibiting
corniﬁed cells with no leukocytes for ≥ 3 days
and extended diestrus as the presence of leuko-
cytes for ≥ 4 days (Cooper et al. 1999). 
Radioimmunoassays. We analyzed serum
samples from 60-day-old offspring euthanized
between 0800 (1 hr after lights on) and
1500 hours (6 hr before lights out), in the
diestrus stage of the estrous cycle, for PRL, LH
and TSH, and we analyzed anterior pituitaries
for PRL and LH by radioimmunoassay, as pre-
viously described by Cooper et al. (2000). We
moved all animals to holding rooms the day
before necropsy and euthanized them as
rapidly as possible to minimize the stress effect
of movement and handling on hormone levels.
We performed the assays using the following
materials supplied by the National Institute of
Arthritis, Diabetes, Digestive, and Kidney
Diseases for LH, PRL, and TSH, respectively:
iodination preparation I-10, I-6, I-9; reference
preparation RP-3, RP-3, RP-3; and antisera
S-11, S-9, S-6. The iodination preparation was
radiolabeled with Na125I (Dupont/New
England Nuclear, Boston, MA) by a modi-
fication of the chloramine-T method of
Greenwood et al. (1963). We serially diluted
standard reference preparations for the
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Figure 2 Overview of the study protocol. Timed-pregnant (plug+) Long-Evans rats (6–12 per treatment
group per block, 2 blocks) were orally gavaged with twice-daily half-dose treatment of 0, 0.09, 0.87, or
8.73 mg AMM/kg bw/day or 100 mg ATR/kg bw/day on GD15–GD19. Female offspring were weighed at
each necropsy (Necr) time point beginning at PND4 until the end of the study (PND60). Pups were weaned
between PND22 and PND25, and onset of puberty was evaluated by day of VO beginning on PND28.
Estrous cyclicity was monitored by smears beginning on PND42. 
Plug+ Dosing Necr Necr Necr Necr Necr
Day 0d 15–19 4 22–25 33 40 60
GD Birth PND
Wean VO Smears
Table 1. Formulation of AMM.
Compound in  Compound in AME  Adj ppm  Conc in stock
Compound FW AME  AMM (%) AMM (ppm)a (adj ppm)b (%)c (mg/kg)d 
ATR 215.7 1 25 62.5 62.5 20.5 1.786
DACT 145.5 1.482 35 87.5 129.7 42.5 3.706
HA 197.2 1.094 20 50.0 54.7 17.9 1.563
DEA 187.7 1.149 15 37.5 43.1 14.1 1.231
DIA 173.7 1.242 5 12.5 15.5 5.1 0.443
Total 100 250.0 305.5 100 8.729
Abbreviations: Adj, adjusted; AME, adjusted molar equivalent of ATR (ATR FW/metabolite FW); Conc, concentration; FW,
formula weight. 8.73 mg AMM/kg bw = 250 ppm. 
aThe ppm value of % in AMM. bAMM % as ppm adjusted to reflect the AME. cCompound % of AME adjusted ppm.
dAmount in the highest mixture dose. Assuming 2-L consumption and 70-kg bw for a human, [AME adj ppm (as mg)/L] ×
(2 L/day) × (1 /70 kg) = mg/kg/day. standard curves. Serum samples and anterior
pituitary homogenates were diluted (as appro-
priate) to a final volume of 500 µL in
100 mM phosphate buffer, containing 1%
bovine serum albumin (BSA). We ran quality
control standards at the beginning and end of
each assay. Assay tubes containing 200 µL pri-
mary antisera in 100 mM potassium phos-
phate, 76.8 mM EDTA, 1% BSA, and 3%
normal rabbit serum were vortexed and incu-
bated then at 4°C for 24 hr. We added
100 µL iodinated hormone to each tube, vor-
texed the contents, and incubated the tubes
for 24 hr. We then added secondary antibody
(goat anti-rabbit gamma globulin, 1 unit/
100 µL; Calbiochem, San Diego, CA), vor-
texed the tubes, and incubated them for 24 hr.
We centrifuged the samples at 1,260 × g for
30 min, aspirated the supernatant, and
counted the sample tube, with pellet, on a
gamma counter. We performed the assays in
duplicate, and all assay coefﬁcients of variation
were < 10%. We adjusted data for sample
dilution and volume. 
Fetal weight study. We conducted these
studies exactly as described in Rayner et al.
(2005). Timed-pregnant Long-Evans dams
were treated with 0 or 8.73 mg AMM/kg bw
(n = 8 dams/treatment) on GD15–GD19 and
euthanized on GD20. We removed the litters
from the dam and recorded the sex and weight
of each fetus. One control dam died during
the study. 
Statistical analysis. We used dam as the
unit of exposure (reported findings as dam
means) for all analyses. We analyzed data for
effects by analysis of variance using the least-
squares means or mixed models in SAS (SAS
Institute, Inc. Cary, NC); p < 0.05 indicates
statistical significance. We assessed replicate
(block) effects for each parameter. Organ
weights were analyzed using both the body
weight at necropsy and the dam as a covariate
(mixed model). We compared experimental
groups with the control group and with each
other (Dunnett’s) and performed categorical
data analyses on cyclicity data. Data are
reported as mean ± SE except where noted. 
Results
Maternal weight gain. Maternal weight gain
was significantly reduced during the dosing
period (less than half of control value) after
ATR-only exposure (p < 0.05). However, we
found no reduction in weight gain during
that period in the AMM-treated dams
(Figure 3). In fact, dams in the lower two
AMM dose groups exhibited a slight increase
in weight gain (7–12% more than controls). 
Offspring body weights. Rayner et al.
(2004) reported that in utero exposure to
100 mg ATR/kg bw during GD15–GD19
reduced pup weight by 6–7% on PND4.
However, in the present study, female off-
spring prenatally exposed to 100 mg ATR/kg
bw were not statistically different in body
weight from control pups (Table 2) at any age
evaluated (data not shown). At PND4, the
mean offspring weight of ATR exposed pups
was 3% less than control pups, which is con-
sistent with the 6% decrease seen in our pre-
vious study (Rayner et al. 2004). Although
the AMM contained 25% ATR, it signifi-
cantly increased the mean bw at PND4 over
that in control pups by 7–8% at all doses
tested (n = 6–12 pups/treatment/block,
p < 0.01; Table 2).
We weighed female offspring at several
time points after PND4. We found no effect
of treatment on mean bw in female offspring at
PND25, PND33, or PND40 (data not
shown). However, on PND60 female offspring
of dams treated with 0.87 and 8.73 mg
AMM/kg bw weighed signiﬁcantly more than
controls (p < 0.05; Table 2). Some of these
effects on bw may be attributed to random
selection of offspring at the individual time
points, but all offspring were weighed at
PND4. To determine whether the difference
in weight of PND4 AMM pups originated
from prenatal exposure or was due to smaller
litter sizes in treated dams (before equalizing
litter size), we conducted a separate study to
evaluate the effects of AMM exposure on fetus
number and fetal body weight at GD20, the
day after the dosing ended. In this study, dams
exposed to 8.73 mg AMM/kg bw had num-
bers of pups similar to controls (12.1 ± 1.4 in
the AMM litter and 13.7 ± 1.0 in the control
litter; n = 7–8 dams/treatment group), and no
dead fetuses were observed in any treatment
group. The weights of both male and female
fetuses of AMM-treated dams were signifi-
cantly higher than those of control dams on
GD20 (Table 3). These data demonstrate that
the apparent increased weight gain of AMM-
exposed offspring present on PND4 stems
from increased fetal weight. These data suggest
that the doses of AMM and ATR used in this
study have opposing effects on maternal and
postnatal offspring body weight gain.
Vaginal opening. We assessed the onset of
puberty of the female offspring by VO. The
day of VO for AMM-treated animals, regard-
less of dose, was similar to that of controls
(Figure 4A). However, when comparing the
weights of pups on their respective day of VO,
we found an effect of AMM exposure on bw.
The animals in the 0.87-mg AMM/kg bw
Enoch et al.
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Figure 3. Body weight gain (g) in control rat dams
or those treated with ATR or AMM during the dos-
ing period (GD15–GD19). Data are presented as
mean ± SE (n = 15–20 dams/group). 
**p < 0.01 compared with controls. 
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Table 3. Effect of gestational exposure to AMM on litter size and fetal bw.
Control AMM (8.73 mg/kg)
Live fetuses/litter 13.71 ± 1.04 12.13 ± 1.36a
Resorptions/litter 0 0.75 ± 0.25
F fetus bw (g) 1.97 ± 0.03 2.14 ± 0.03**
M fetus bw (g) 2.00 ± 0.03 2.19 ± 0.03**
F + M fetus bw (g) 1.99 ± 0.02 2.16 ± 0.02**
Abbreviations: F, female; M, male. Data are presented as mean ± SE; n = 7 litters for control, n = 8 litters for AMM. 
aNo dead fetuses. **p < 0.01 compared with controls. 
Figure 4. Effect of AMM on day of VO (A) and weight at VO (B). Data are presented as mean ± SE; n ≥ 10
pups/treatment. 
**p < 0.01 compared with controls.
Control 0.09 0.87 8.73
33.5
33.0
32.5
32.0
31.5
31.0
P
N
D
AMM (mg/kg)
A
Control 0.09 0.87 8.73
150
140
130
120
110
B
o
d
y
 
w
e
i
g
h
t
 
(
g
)
** B
AMM (mg/kg)
Table 2. Effect of AMM and ATR (mg/kg) on bw (g) of female offspring.
Control 0.09 AMM 0.87 AMM 8.73 AMM ATR
PND4 10.03 ± 0.13 10.80 ± 0.16# 10.77 ± 0.17** 10.69 ± 0.17** 9.68 ± 0.21
PND60 252.7 ± 2.0 254.5 ± 4.8 271.8 ± 6.4* 269.0 ± 5.2* 262.8 ± 7.1
Data are presented as mean ± SE; n ≥ 10 pups/treatment.
*p < 0.05, **p < 0.01, and #p < 0.001, compared with controls. group were signiﬁcantly heavier than control
offspring (p < 0.001) at the time of VO, as
were the females in the 0.09-mg/kg AMM
group (p = 0.052; Figure 4B). 
Mammary gland development. We com-
pared the carmine-stained mammary epithelia
of AMM- and ATR-exposed animals to that
of controls by whole-mount analysis on
PND4, at weaning, and on PND33, PND40,
and PND60, denoting the developmental
score within an age group after comparison of
all slides receiving a similar score (as described
in “Materials and Methods”). We found a sig-
nificant effect of AMM exposure on growth
and development of glands; signiﬁcant delays
were seen at each of these time points except
PND33 (Table 4; development in the
PND33 control group was unusually poor
compared with that of historical controls);
these developmental delays were consistently
detectable in whole mounts of the fourth and
ﬁfth inguinal glands (Figure 5). At weaning,
PND40, and PND60 the glands of all
exposed females were significantly different
from those of controls (p < 0.0001). This was
also true at PND4 for the 0.87-mg AMM/kg
bw and ATR exposure groups (p < 0.01) and
at PND33 for the 8.73-mg AMM/kg bw and
ATR exposure groups (p < 0.05). The AMM
and ATR-exposed animals at PND4 had
delayed migration of the epithelium through
the mammary fat pad and limited lateral
branching from the primary and secondary
ducts compared with controls. Typically, at
PND33, glands 4 and 5 have grown together,
and differentiation of terminal end buds
(TEBs) is apparent in control animals.
However, in this group of control animals,
that was not the case, causing the average
control score to be lower than that previously
observed in this strain of rat (Fenton et al.
2002; Rayner et al. 2004, 2005). The control
glands at PND4 were also not as well devel-
oped as expected. 
The effects of the AMM exposure were
persistent. Although TEB had differentiated
and lobules were regressing in control animals
at PND60 (maturity), differentiation within
the fat pad of exposed animals was hindered as
treatment dose was increased. This was partic-
ularly evident in the glands of 8.73-mg AMM/
kg bw and ATR-exposed animals (Figure 5).
The mammary gland developmental scores
were equivalent in those two dose groups over
time (even though there is a > 10-fold differ-
ence in total dose). No histopathologic lesions
(dysplasia) were noted in the mammary glands
of these animals; we conﬁrmed the presence of
TEB at PND60 in AMM-exposed animals via
histology (not shown).
Reproductive tract and cyclicity evaluation.
Organ weights of sexually mature female off-
spring evaluated in diestrus are shown in
Table 5. We analyzed these data by treatment
group and weighted the data by dam and bw
using a mixed-model approach. There was a
signiﬁcant effect of AMM exposure on pitui-
tary and ovary weights (p < 0.05). The pre-
natally AMM-exposed females demonstrated a
14–19% increase in pituitary weight at
PND60. However, ovary weight was signifi-
cantly increased only in offspring exposed to
0.09 mg AMM/kg bw (p < 0.01), whereas the
uterine weight of ATR-exposed females was
decreased slightly compared with controls.
We examined the uteri from diestrus ani-
mals microscopically for lesions/abnormalities
or inﬂammation. We detected no differences
for AMM or ATR-treated females compared
with either controls or each other (data not
shown). We also microscopically evaluated
both ovaries from each sexually mature female
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Table 4. Effects of AMM (mg/kg bw/day) on mammary gland scores.
PND Control 0.09 AMM 0.87 AMM 8.73 AMM ATR
4 3.27 ± 0.28 2.52 ± 0.18 2.00 ± 0.39** 2.47 ± 0.18 2.03 ± 0.31**
25  3.83 ± 0.08 2.87 ± 0.11# 2.50 ± 0.07# 2.55 ± 0.12# 2.10 ± 0.28#
33a 2.50 ± 0.25 2.28 ± 0.23 2.15 ± 0.22 1.75 ± 0.21* 1.70 ± 0.13
40  3.40 ± 0.11 2.32 ± 0.16# 2.13 ± 0.11# 1.83 ± 0.10# 1.93 ± 0.17#
60 3.25 ± 0.05 2.39 ± 0.13# 2.06 ± 0.11# 1.81 ± 0.05# 1.75 ± 0.08#
Data are presented as mean ± SE; n ≥ 10 pups/treatment. Score: 1 = stunted growth pattern; 4 = normal growth for age. 
aUnusually poor development in the control group compared with historical controls. *p < 0.05, **p < 0.01, and #p < 0.001
compared with controls. 
Figure 5. Mammary gland whole mounts from female offspring prenatally exposed to AMM or ATR (mg/kg
bw/day). Images (at 16 × magnification) represent the mean scores for each treatment and age as indi-
cated in Table 4, and illustrate significant changes with increased AMM exposure, such as fewer and
smaller ductal buds and lateral branching (PND4); undifferentiated end buds and glands not grown
together (PND33); and TEBs, large lobuloaveolar units, and immature branching (PND60). Large dark struc-
tures present in a few segments are stained lymph nodes. Bars = 2 mm. 
Control
0.09 AMM
0.87 AMM
8.73 AMM
100 ATR
PND4 PND33 PND60Enoch et al.
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to ensure that normal follicular and luteal
structures were present. We detected no differ-
ences between AMM-treated, ATR-treated, or
control ovaries (data not shown). In agree-
ment with these histopathologic results, there
was no signiﬁcant effect of treatment on early
estrous cyclicity (data not shown). The major-
ity of animals in all groups were cycling nor-
mally. In all treatment groups (n = 7 controls;
n = 10–20/treatment group) at least one ani-
mal displayed a single prolonged diestrus or
estrus event, or had an abnormal cycle length.
However, in the ATR-exposed group, 4 of
10 females had cycles ≥ 6 days long. This was
also seen in our previous studies (Rayner et al.
2004).
Hormone analysis. Hormone concentra-
tions from 60-day-old offspring in the
diestrus stage of the estrous cycle are shown in
Table 6. We found a significant effect of
treatment on pituitary PRL concentrations.
The animals exposed to 0.87 mg AMM/kg
bw and ATR were signiﬁcantly different from
control animals (p < 0.05 and p < 0.01,
respectively). Although the ATR-induced
serum PRL levels were only about 40% of
those found in controls, we detected no other
significant effects of treatment on serum or
pituitary hormones in the study (including
TSH, not shown). 
Discussion
This study is the first to report exposure of
rodents to a mixture of ATR and its environ-
mental metabolites. We report effects on
reproductive tissue development following
acute gestational exposure to relatively low
doses of ATR metabolites in the rat. The data
demonstrate that an acute 5-day exposure to
AMM during late pregnancy has a signiﬁcant
impact on mammary growth and develop-
ment, with delayed development prominent as
early as PND4 and effects evident in all treat-
ment groups at weaning. Fetal mammary
development has previously been shown to be
sensitive to high-dose ATR (Rayner et al.
2004, 2005), as well as other environmental
contaminants (Fenton et al. 2002; Johnson
et al. 2003; Markey et al. 2001; White et al.
2006). However, this same low dose of AMM
did not impact onset of VO (a typical indicator
of puberty in rodents) or signiﬁcantly reduce
mean bw in the offspring or treated dams.
Importantly, the lowest AMM dose used in
our study (0.09 mg/kg bw), containing only
25% ATR (by weight), caused persistent delays
in mammary development that were still evi-
dent at PND60. These levels of ATR metabo-
lites are below the current acute developmental
NOAEL for ATR of 6.25 mg/kg/day. In previ-
ous work (Rayner et al. 2005), delays in mam-
mary development into adulthood (such as
those we found on PND60) resulted in adverse
effects on weight gain of F2 pups without fur-
ther exposure, possibly due to insufﬁcient milk
production of the F1 ATR-exposed dams’
underdeveloped mammary glands. The long-
term impact of mammary effects from this
low-dose mixture is not yet known.
Previous studies in female Wistar rats have
shown that extended peripubertal exposure to
ATR at doses as low as 50 mg/kg bw/day
(PND21–PND41) delayed puberty (Laws et al.
2000). Delayed VO in Long-Evans rats has
been consistently observed with late gestational
and/or residual lactational ATR exposure
(Rayner et al. 2004, 2005). However, unlike
ATR, our data demonstrate no signiﬁcant effect
on VO from the low-dose AMM–exposed
females. Our data, showing perturbation of
mammary development in female offspring
after prenatal AMM exposure well before the
hormones of puberty have begun to increase
(PND4 and PND22), emphasize that mam-
mary gland development and VO may not be
regulated by similar signaling pathways or
modes of action. Further, mammary gland
development is more sensitive to the effects of
ATR and its metabolites than is VO. This is
consistent with effects observed following lacta-
tional and in utero exposure to ATR, where we
have shown that GD15–GD19 is a critical
period for growth and development of the
mammary glands but not for other female
reproductive tissues (Rayner et al. 2004, 2005).
This sensitivity could arise because mammary
gland growth and development may be directly
responsive to these compounds (e.g., more
compound burden in this tissue), the assay for
discerning the effects may be considerably more
sensitive (whole mount analysis vs. VO), or the
latter part of gestation and early lactation (time
of exposure) are sensitive periods for mammary
gland development, but not for VO timing. 
Although there are no other published
studies that have evaluated short gestational
exposures to ATR and its metabolites, Stoker
et al. (2002) have shown that exposure to indi-
vidual ATR metabolites in male Wistar rats
treated for the entire peripubertal period
(PND23–PND53) caused a decrease in mean
bw of the animals, as well as a delay in puberty.
In the present study, we found no indication of
reduced bw in females exposed to AMM (pups
or dams), but a signiﬁcant increase in bw was
noted on PND4 and PND60. In Wistar rats,
no ATR-induced effects on puberty were seen
at doses < 50 mg/kg bw/day (Laws et al. 2000).
Because our highest dose of AMM
(8.73 mg/kg bw/day) contains only 25% ATR
(1.79 mg/kg bw/day), we did not expect to
observe a change in the timing of puberty.
However, all doses of AMM affected the mam-
mary and anterior pituitary glands. The ante-
rior pituitary gland may also be sensitive to the
effects of exposure to AMM because the signif-
icant increases in weight of this tissue following
exposure to AMM are reminiscent of the sig-
niﬁcant changes seen on PND58 in a previous
study (Rayner et al. 2004) using 100 mg
ATR/kg bw on GD15–GD19. 
Our data [the present study and Rayner
et al. (2004, 2005)] indicate that mammary
gland growth and development in the female
appear to be signiﬁcantly affected by low-level
AMM and ATR exposure in utero. It has been
previously suggested that decreased body
weight is correlated with decreased or delayed
mammary gland development in virgin mice
(Engelman et al. 1994) and that toxicant-
induced decreases in bw can cause delayed
puberty (Stoker et al. 2000). However, we
observed no decrease in mean bw or hormone
levels, or delay in onset of puberty that coin-
cides with the developmental delays of the
mammary gland. Interestingly, our data
demonstrate a gain in bw in AMM-exposed
fetuses as early as GD20. Delayed mammary
growth and development following deletion of
genes known to be involved in puberty and
growth has also been shown in various knock-
out mouse lines, implicating changes in
puberty or endocrine hormone levels as possi-
ble mechanisms (Walker and Korach 2004).
We detected little change in serum or pituitary
hormone levels between controls and offspring
Table 6. Effect of AMM (mg/kg bw/day) on female hormone levels at PND60.
Control  0.09 AMM 0.87 AMM 8.73 AMM ATR
sPRL (ng/mL) 10.10 ± 1.86 7.21 ± 1.28 9.21 ± 2.16 8.79 ± 3.98 3.83 ± 0.72
pPRL (ng/mg) 1,443 ± 101 1,595 ± 86 2,045 ± 116** 1,431 ± 94 2,052 ± 427*
sLH (ng/mL) 0.289 ± 0.030 0.343 ± 0.052 0.397 ± 0.138 0.377 ± 0.086 0.331 ± 0.066
pLH (ng/mg) 885 ± 45 924 ± 57 1,039 ± 81 763 ± 50 755 ± 46
Abbreviations: p, pituitary gland; s, serum. Data are presented as mean ± SE; n ≥ 10 pups/treatment. 
*p < 0.05, and **p < 0.01 compared with controls.
Table 5. Effect of AMM (mg/kg bw/day) on female organ weight.
Control 0.09 AMM 0.87 AMM 8.73 AMM ATR
Pituitary (mg) 9.1 ± 0.4 10.8 ± 0.3** 10.4 ± 0.3** 10.6 ± 0.4** 9.6 ± 0.5
Ovary (mg) 106.6 ± 3.6  131.0 ± 5.9** 112.7 ± 4.4 121.1 ± 3.9 114.2 ± 5.5
Uterus (g)  328.6 ± 13.8 317.7 ± 12.0 352.8 ± 24.1 311.8 ± 19.7 292.6 ± 16.0
Data are presented as mean ± SE; n ≥ 10 pups/treatment. Signiﬁcant effects of treatment were observed using pup bw as
a covariate. 
**p ≤ 0.01 compared with controls. exposed to ATR or AMM in utero. In the
female offspring, pituitary PRL concentrations
were significantly higher in both ATR and
mid-dose AMM-exposed groups than in con-
trols. However, all of our measured values
appear to be elevated beyond the normal phys-
iologic concentrations of about 1,006 ±
104 ng/mg tissue (Cooper et al. 1999), and
may be typical for young female rats (60 days
of age vs. 90 or 120 days of age). 
In conclusion, acute administration of the
mixture of ATR and its metabolites during
gestation had a signiﬁcant effect on mammary
growth and development in female offspring
and these effects persisted into adulthood. The
doses of AMM necessary for these effects were
> 10-fold lower than doses of ATR previously
shown to induce mammary developmental
delays. This finding brings attention to the
fact that the metabolites of the chlorotriazines
deserve attention. The fate and elimination
kinetics of the mixed ATR metabolites may
differ from those of ATR alone, resulting in
these low-dose effects. It is also possible that a
single metabolite is responsible for these
effects, or that ATR or one of the metabolites
present in the AMM persists for a longer time
in the pregnant and lactating rat, theoretically
extending the actual exposure period. 
Studies are under way to investigate the
particular metabolite—or combination of
metabolites—responsible for the effects
observed in the present study; also, studies are
being conducted to address whether these are
direct effects on mammary cells or an indirect
effect. Further studies into the critical ele-
ments of neonatal mammary gland develop-
ment are necessary to clarify the effects of
these low-dose (particularly at 0.09 mg/kg),
short-term exposures to ATR and its metabo-
lites. Once a mechanism of action for chloro-
triazine metabolites on mammary tissue has
been determined, it will be important to con-
sider the many similarities between mecha-
nisms regulating growth and differentiation in
human and rat mammary glands [such as
timing of appearance of mammary structures
and bud outgrowth (Fenton 2006)] in order
to determine the potential relevancy of these
ﬁndings with respect to human health.
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